ABS Global v. Inguran: Federal Circuit Appeal Voluntarily Dismissed After 532 Days
ABS Global and Genus PLC pursued a Federal Circuit infringement appeal against Inguran, XY LLC, and Cytonome/ST LLC across seven patents covering sperm cell sorting, cryopreservation, and hydrodynamic sheath flow systems. The parties jointly moved to dismiss under Fed. R. App. P. 42(b) after 532 days, with each side bearing its own costs — leaving no merits ruling on record.
A high-stakes cell-sorting IP dispute ends without a Federal Circuit merits ruling
ABS Global, Inc. and Genus PLC filed this Federal Circuit appeal (Case 22-2098) on 3 August 2022 against Inguran LLC, XY LLC, and Cytonome/ST LLC. The dispute centred on seven US patents protecting core technologies in sexed-semen production: sperm cryopreservation methods (US8529161B2, US9365822B2), sheath fluid and cytometer sorting systems (US6524860B1, US7311476B2, US7611309B2), cell sorting systems (US9446912B2), and multilayer hydrodynamic sheath flow structures (US7208265B1) — together covering the principal steps of high-throughput sex-sorted sperm technology.
The appeal closed on 17 January 2024 when both sides jointly moved to dismiss under Federal Rule of Appellate Procedure 42(b), with each party bearing its own costs. The Federal Circuit granted the motion. Crucially, this is a procedural termination: the court issued no ruling on the merits of the underlying infringement claims, validity of any of the seven patents, or any damages question. The public record does not specify whether the dismissal reflects an out-of-court settlement, a commercial agreement, or a strategic recalibration by either side.
The 532-day duration — spanning the full appellate briefing window — suggests the parties engaged seriously with the appeal before agreeing to withdraw it. The equal cost-bearing arrangement is consistent with a negotiated resolution rather than a concession by either side, though the public record is silent on underlying terms. Seven patents remaining unlitigated on their merits leaves the IP landscape in sexed-semen technology meaningfully unsettled, and any licensing or competitive arrangements reached privately will not be visible from court filings alone.
Filing to Voluntary dismissal in 532 days
532 days at the Federal Circuit — appeals in this court typically resolve in 12–18 months
Voluntary Federal Circuit dismissal: what the joint motion means for both parties
Fed. R. App. P. 42(b): joint dismissal, no merits reached
Rule 42(b) allows parties to jointly dismiss an appeal at any stage, without court adjudication of the underlying issues. The Federal Circuit’s order simply grants the motion — it makes no findings on infringement, invalidity, or claim construction. This means the lower court record stands as-is, and no Federal Circuit precedent is created by this case on any of the seven patents in suit.
No merits rulingWith or without prejudice? The public record is silent
Rule 42(b) dismissals can operate with or without prejudice to re-filing, but the order in this case specifies neither. The Basis of Termination states only ‘Voluntary dismissal.’ This distinction matters significantly: a without-prejudice dismissal preserves the right to re-assert these claims; a with-prejudice dismissal forecloses them. Practitioners should not assume either outcome — the underlying agreement between the parties, if any, would control, and that agreement is not public.
Prejudice terms undisclosedABS Global and Genus: appeal withdrawn, seven patents unvalidated
As appellants, ABS Global and Genus PLC initiated this appeal and chose to withdraw it. Without a Federal Circuit merits ruling, they obtain no appellate vindication of the seven asserted patents. The patents remain in force but carry the litigation history of an unresolved appeal. Whether the withdrawal reflects a favourable private arrangement or a reassessment of appellate prospects is not discernible from the public record.
Patents in force, unlitigated on appealSeven sexed-semen patents left without appellate clarity
The voluntary dismissal leaves significant IP ambiguity in the high-value sexed-semen and cell-sorting technology sector. Competitors, licensees, and R&D teams operating near these patent claims — covering cryopreservation, hydrodynamic sheath flow, and cytometer-based sex sorting — cannot rely on this case for claim scope guidance. FTO assessments for these seven patents must rest on the underlying district court record and USPTO prosecution history, not on any Federal Circuit interpretation.
FTO landscape unchangedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | ABS Global, Inc. | Company | Animal genetics and bovine sexed-semen technology company — holder of US8529161B2 and six further sorting patentsSearch in Eureka ↗ |
| Co-Plaintiff | Genus, PLC | Company | Search in Eureka ↗ |
| Defendant | Inguran, LLC | Company | Inguran LLC (d/b/a STgenetics), XY LLC, and Cytonome/ST LLC — sexed-semen processing and cell-sorting technology providersSearch in Eureka ↗ |
| Co-Defendant | XY, LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Cytonome/ST, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Madeleine Joseph | Attorney | Counsel for ABS Global, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Stephanie P. Koh | Attorney | Counsel for ABS Global, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Steven J. Horowitz | Attorney | Counsel for ABS Global, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Thomas D. Rein | Attorney | Counsel for ABS Global, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Sidley Austin LLP | Law Firm | Representing ABS Global, Inc.Search in Eureka ↗ |
| Defendant counsel | Daniel Lynn Moffett | Attorney | Counsel for Inguran, LLCSearch in Eureka ↗ |
| Defendant counsel | Pratik A. Shah | Attorney | Counsel for Inguran, LLCSearch in Eureka ↗ |
| Defendant counsel | Z.W. Julius Chen | Attorney | Counsel for Inguran, LLCSearch in Eureka ↗ |
| Defendant counsel | Zhen He Tan | Attorney | Counsel for Inguran, LLCSearch in Eureka ↗ |
| Defendant law firm | Akin Gump Strauss Hauer & Feld, LLP | Law Firm | Representing Inguran, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The order’s phrasing — ‘The motion is granted’ in response to a joint Rule 42(b) motion — is purely procedural. The Federal Circuit made no finding on infringement, claim construction, or patent validity for any of the seven asserted patents. Because both parties moved jointly, neither is designated a prevailing party for costs purposes, consistent with the explicit ‘each side to bear its own costs’ term. This outcome creates no binding or persuasive appellate precedent on the underlying substantive patent questions.
US8529161B2 and six further patents — sperm sorting, cryopreservation, and cytometer systems
The seven patents in suit span the principal process steps in commercial sexed-semen production. US8529161B2 and US9365822B2 address downstream cryopreservation of sex-selected sperm, protecting the formulation and freezing steps that preserve sorted cells for commercial use. US6524860B1 and US7208265B1 cover hydrodynamic sheath flow structures — the microfluidic architecture that controls cell alignment and spacing within flow cytometers. US7311476B2, US7611309B2, and US9446912B2 address the broader cytometer sorting system and sex-specific collection methodology. Together, the portfolio covers the full workflow from cell preparation through sorting and preservation.
Sexed-semen technology commands significant commercial value in livestock genetics — sorted semen commands a substantial price premium over conventional product, and the underlying cytometer and microfluidic IP constitutes a meaningful barrier to competitive entry. A portfolio spanning both process (cryopreservation) and apparatus (sheath flow, cytometer system) claims is strategically broad, since design-arounds to one layer typically encounter the other. The involvement of XY LLC — a historically dominant holder of sexed-semen IP — and Cytonome/ST, a specialist in microfluidic cytometry, confirms that this dispute touched the core of competitive differentiation in the sector.
Should you run an FTO against US8529161B2 and the six co-asserted sperm-sorting patents?
Any company developing or commercialising sexed-semen production systems, high-throughput sperm sorting instruments, microfluidic sheath flow components, or cell-sorting cytometers for reproductive applications should treat these seven patents as live FTO targets. The voluntary Federal Circuit dismissal creates no safe harbour — the patents remain in force, no claim has been cancelled or narrowed by this proceeding, and the parties’ enforcement posture post-dismissal is unknown. This applies equally to equipment manufacturers, contract sexing services, and agricultural biotech companies licensing the underlying platform.
PatSnap Eureka’s FTO Search Agent can map each of the seven patent claim sets against your product specifications, flag prosecution history disclaimers that narrow enforceability, and surface prior art that may support validity challenges. Given the multi-layer nature of this portfolio — apparatus, method, and composition claims across seven patents — automated claim-by-claim landscaping is materially more efficient than manual review. Eureka can also monitor each patent for post-grant proceedings, continuations, or new assignments that may change the enforcement landscape.
Run a freedom-to-operate analysis on US8529161B2 to assess your product’s exposure
Run FTO in Eureka →Related Federal Circuit appeals in sperm-sorting and cell cytometry patent disputes
Federal Circuit cases involving sexed-semen, flow cytometry, and microfluidic cell-sorting patents — including prior ABS Global and XY LLC litigation history.
What this case signals for the sexed-semen and cell-sorting IP landscape
A joint dismissal across seven core patents signals active commercial dynamics in this sector — and leaves enforcement risk unresolved for competitors.
Seven unresolved patents mean ongoing FTO risk for cell-sorting competitors
The absence of any Federal Circuit merits ruling means all seven patents — covering cryopreservation, hydrodynamic sheath flow, and cytometer sorting — remain live enforcement tools. Companies developing or deploying sexed-semen technology should treat these patents as fully enforceable and conduct claim-by-claim FTO analysis against current product designs.
Joint cost-bearing suggests a negotiated resolution, not capitulation
When appellate parties split costs equally rather than awarding them to a prevailing side, it typically signals a bilateral agreement rather than a unilateral withdrawal. For licensing professionals, this pattern is consistent with a settlement or cross-licensing arrangement — though the specific terms remain private and should not be assumed.
ABS v Inguran — key questions answered
The Federal Circuit appeal (Case 22-2098) was voluntarily dismissed by joint motion of all parties under Fed. R. App. P. 42(b) on 17 January 2024, after 532 days. Each side bears its own costs. The court issued no ruling on the merits of infringement or validity for any of the seven asserted patents.
Seven US patents were asserted: US8529161B2 (sperm cryopreservation), US9365822B2 (sheath fluid improvement methods), US6524860B1 (multilayer hydrodynamic sheath flow structure), US7311476B2 (cell sorting system), US7611309B2 (sex-specific cytometer sorting), US9446912B2 (cell sorting system and method), and US7208265B1 (sex-selection cytometry methods).
No. A Rule 42(b) voluntary dismissal does not cancel, narrow, or invalidate any patent claim. All seven patents remain in force as issued. The dismissal creates no Federal Circuit precedent on claim scope or validity. Enforceability must be assessed against USPTO grant history, prosecution file wrappers, and any district court record from the underlying proceedings.
In Federal Circuit practice, appellate costs (filing fees, reproduction costs) are typically awarded to the prevailing party. When parties agree each side bears its own costs in a joint dismissal, neither is designated the prevailing party. This is commercially consistent with a negotiated resolution and avoids any cost-shifting — though the underlying financial terms of any settlement remain private.
The defendants are Inguran LLC (the primary respondent, operating as STgenetics), XY LLC (a major holder of sexed-semen IP), and Cytonome/ST LLC (a microfluidic cytometry technology company). Their combined involvement suggests the appeal implicated both the biological processing and the cytometric instrumentation dimensions of sexed-semen technology.
PatSnap Eureka searches patents and litigation data to answer instantly.